| 8.47 Data as of 2:59pm ET |  -0.13 / -1.51%Today’s Change | 7.25 Today|||52-Week Range 17.92 | -36.36% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $244.0M |
Company Description
Starpharma Holdings Ltd. develops dendrimer products for pharmaceutical, life science and other applications. Dendrimers are synthetic nanoscale polymer that is regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its lead product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Melbourne, Australia.
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| Jackie K. Fairley, PhD, MBA | Chief Executive Officer & Executive Director |
| Nigel J. Baade, CPA | Chief Financial Officer |
| David J. Owen, PhD | Vice President-Research |
| C. Paul Barrett, PhD | Vice President-Business Development |
| Filippa Shub, MBA | Director-Intellectual Property |
.
